Radek Ampapa

Defining secondary progressive multiple sclerosis

Johannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis et al. · Brain · 2016 · 416 citations · Full text

Life Sciences, Neurology, Neuroscience +12

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

Daniel S. Reich, Douglas L. Arnold, Patrick Vermersch et al. · The Lancet Neurology · 2021 · 192 citations · Full text

Medicine, Neurology, Pharmacology +9

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

Diego Cadavid, Michelle Mellion, Raymond Hupperts et al. · The Lancet Neurology · 2019 · 185 citations

Life Sciences, Immunology, Neurology +11

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

Tomáš Kalinčík, J William L Brown, Neil P. Robertson et al. · The Lancet Neurology · 2017 · 162 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +16

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response

Tomáš Kalinčík, Ali Manouchehrinia, Lukáš Sobíšek et al. · Brain · 2017 · 149 citations · Full text

Public Health, Biostatistics, Clinical Epidemiology +15